Inclusion Criteria:
1. Healthy male between 18 and 64 years of age, inclusive.
2. For male participants with a female partner of childbearing potential, the contraception requirements for participation required the use of a condom by the male in addition to either one other highly effective method of contraception, or one other effective method of contraception by the female partner, if applicable, from first dose until 3 months after last dose.
3. Body mass index (BMI) of 18-30 kg/m2.
4. No clinically significant history of previous allergy / sensitivity to the investigational medicinal product (IMP) or any of the excipients contained within the IMP(s).
5. No clinically significant abnormal test results for serum biochemistry, hematology and/or urine analyses within 28 days before the first dose administration of the IMP.
6. Negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP.
7. Negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
8. No clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IMP including a PR interval \> 220 ms, QT interval corrected using Fridericia's formula QTcF \> 450 ms.
9. No clinically significant abnormalities in vital signs (blood pressure/heart rate, respiratory rate, oral temperature) determined within 28 days before first dose of IMP.
10. Available to complete the study (including all follow-up visits).
11. Satisfied an Investigator about participant fitness to participate in the study.
12. Provided written informed consent to participate in the study.
Exclusion Criteria:
1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
2. Allergic reaction to the IMP or history of reaction to relevant supplements.
3. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP.
4. Evidence of any clinically significant history or the presence of renal, hepatic, respiratory, cardiovascular (hypertension, unstable angina, arrhythmia, QT prolongation, etc.), metabolic dysfunction, hematological, lymphatic or neurological diseases.
5. Disorders of the central nervous system, psychiatric disorders, behavioral/behavior disturbances (e.g., cerebrovascular events, depression, post-traumatic stress disorder \[PTSD\], anxiety, bipolar disorder, severe migraine, Parkinson's disease).
6. History of narrow angle glaucoma.
7. Have had a tattoo or piercing in the 3 months prior to Screening.
8. Reported having experienced suicidal ideation (Type 4 or 5 on the Columbia-Suicide Severity Rating Scale \[C-SSRS\]) within 28 days prior to Screening, any suicidal behavior within 2 years prior to Screening (any "Yes" answers on the Suicidal Behavior section of C-SSRS), and/or the Investigator assessed the participant to be a safety risk to himself/herself or others.
9. Past history of prostate cancer, benign prostatic hyperplasia (BPH) or other clinically significant prostate disease.
10. Concomitant disease or condition that could have interfered with, or treatment which may have interfered with, the conduct of the study, or that would, in the opinion of the investigator, have posed an unacceptable risk to the participant in this study.
11. Concomitant use of CNS medications (including anti-depressants, anti-psychotics), tramadol, topical anesthetics, phosphodiesterase 5 (PDE5) inhibitors or vasoactive penile injection therapy.
12. A clinically significant current or history of drug or alcohol abuse (defined as the consumption of more than 14 units \[for male participants\] of alcohol a week) within the past two years.
13. Inability to communicate well with the Investigators (i.e., language problem, poor mental development or impaired cerebral function).
14. Participation in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within the 30 days or five half-lives, whichever is longer, before the first dose of IMP. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study.)
15. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
16. Vegans, vegetarians or other dietary restrictions (e.g., restrictions for medical, religious or cultural reasons, etc.). Participants who preferred vegetarian options can be included if willing to follow available clinic meal options and all study procedures.
17. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to Screening or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).
18. Participants who received a COVID-19 vaccine injection within 28 days prior to the first dose of IMP.
19. Participants with pregnant or breastfeeding partners.
20. Clinically significant maxillofacial pathology or tongue piercings in the 3 months prior to Screening (Formulation Effect only).
